18 July 2018 - Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.

The offer, details of which were first revealed by Cystic Fibrosis Trust chief executive David Ramsden, who tweeted a letter he received from John Stewart, NHS England’s Director of Specialised Commissioning, would see NHS England pay Vertex around £500 million over the next five years and over £1 billion over the next 10 years for its existing and future CF therapies.

If accepted, the proposal would guarantee “immediate and expanded access” to Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), as well as Symdeco from the date it is licensed for use in the UK, Stewart wrote.

Read Pharma Times article